-The Hindustan Times Far from the neatly trimmed lawns of India Gate that so often reverberate with cries for justice, far also from the corridors of power where ministries recently squabbled over the right age for consensual sex, lie 197 districts - yes 197, read the figure again - where children are regularly abused. In these districts -- all ridden by conflict -- words like illegal detention, arbitrary arrests, sexual violence, torture...

-Tehelka With 65 percent of the population below the age of 35, India boasts of an unparalleled generational dividend, but are we turning this potential into a disaster? Avalok Langer spots a ticking time bomb Nutrition & Health* 40% of children in India are malnourished 43% of children in the age group of 12-23 months receive full immunisation 48%+ of children are underweight 50%+ of all deaths under age 5 are related to malnutrition 45% of children...

-The Economic Times Tribal affairs minister Kishore Chandra Deohas reportedly written to the governors of nine states asking them to cancel mining concessions granted in violation of the law. The Forest Rights Act of 2006 mandates the permission of the gram sabha of a tribal community for using their habitat for purposes other than customary use. So, if mining leases have been granted without the permission of gram sabhas on tribal land,...

-The Hindu     Drug patents are designed to create profits that enable more research on diseases affecting millions. But in practice, they have often generated super profits for big pharma companies while erecting access barriers for the poor. The Novartis case spotlights much that is wrong with the system. The rejection of the Novartis petition challenging one of the most progressive tenets of the Indian Patents Act (1970), as amended in 2005 by...

-The Economic Times WASHINGTON: Big Pharma found little support from the small guy on the street as the Indian Supreme Court's decision to reject patent claims of the drug maker Novartis for its celebrated cancer medicine Glivec reverberated across the world. The pharma lobby railed against the decision but the overwhelming sentiment, from physicians to politicians, from academia to media, particularly in a country groaning from the high cost of health care,...